Cognition Therapeutics, Inc. (CGTX)
NASDAQ: CGTX · Real-Time Price · USD
1.280
0.00 (0.00%)
At close: Apr 28, 2026, 4:00 PM EDT
1.262
-0.018 (-1.42%)
Pre-market: Apr 29, 2026, 4:52 AM EDT
Cognition Therapeutics Employees
Cognition Therapeutics had 14 employees as of December 31, 2025. The number of employees decreased by 14 or -50.00% compared to the previous year.
Employees
14
Change (1Y)
-14
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,677,643
Market Cap
114.37M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Cibus | 118 |
| Immunic | 92 |
| Verrica Pharmaceuticals | 76 |
| Pyxis Oncology | 56 |
| Vivani Medical | 42 |
| Aardvark Therapeutics | 40 |
| Cardiff Oncology | 31 |
CGTX News
- 15 days ago - Cognition Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 21 days ago - Cognition Therapeutics to Present at Needham Virtual Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Cognition Therapeutics CEO Issues Letter to Shareholders - GlobeNewsWire
- 4 weeks ago - Cognition Therapeutics Earnings Call Transcript: Q4 2025 - Transcripts
- 4 weeks ago - Cognition Therapeutics Reports Year End 2025 Financial Results and Provides Clinical Development Update - GlobeNewsWire
- 5 weeks ago - Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Cognition Therapeutics Presents Evidence of Zervimesine's Impact on Neuropsychiatric Symptoms of Dementia with Lewy Bodies at AD/PD 2026 - GlobeNewsWire
- 2 months ago - Cognition Therapeutics Advancing Zervimesine (CT1812) for Dementia with Lewy Bodies (DLB) Psychosis - GlobeNewsWire